Lim EA, Bendell JC, Falchook GS, Bauer TM, et al. Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. Clin Cancer Res 2022;28:4871-4884.
PMID: 36044531